RT Journal Article
SR Electronic
T1 Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and Corticosteroid Therapy: A Multicenter International Observational Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.12.21255323
DO 10.1101/2021.04.12.21255323
A1 Marwa Amer
A1 Mohammed Bawazeer
A1 Khalid Maghrabi
A1 Ahmed M. Kamel
A1 Abid Butt
A1 Talal Dahhan
A1 Eiad Kseibi
A1 Syed Moazzum Khurshid
A1 Mohammed Abujazar
A1 Razan Alghunaim
A1 Muath Rabee
A1 Maal Abualkhair
A1 Ali Al-Janoubi
A1 Abeer Turki AlFirm
A1 Ognjen Gajic
A1 Allan J. Walkey
A1 Jarrod M Mosier
A1 Igor Borisovich Zabolotskikh
A1 Oscar Y Gavidia
A1 Santiago Y. Teruel
A1 Michael A. Bernstein
A1 Karen Boman
A1 Vishakha K. Kumar
A1 Vikas Bansal
A1 Rahul Kashyap
YR 2021
UL http://medrxiv.org/content/early/2021/07/01/2021.04.12.21255323.abstract
AB Objectives The interest in interleukin-6 receptor antagonists (IL-6RA) and steroids have increased recently due to their potential role as immunomodulatory effect in critically ill coronavirus disease (COVID-19). The magnitude of this therapy in subgroups of patients with invasive mechanical ventilation (MV) remains to be fully clarified. We compared the clinical characteristics and outcomes of patients requiring iMV, and receiving IL-6RA and steroids with different steroids regimens.Design International, multicenter, observational study derived from Viral Infection and Respiratory Illness University Study registry and conducted through Discovery Network, Society of Critical Care Medicine. Marginal structural modeling was used to adjust time-dependent confounders; observations were weighted using inverse probability of treatment weight. A sensitivity analysis was conducted for target trial design.Setting 168 hospitals, 16 countries.Patients Covid-19 ICU patients (≥18 years) requiring MV between March 01,2020, and January 10,2021.Intervention None.Measurements and Main Results Of 860 patients met eligibility criteria, 589 received steroids, 170 IL-6RA, and 101 combinations; groups were balanced after adjustment. Median daily steroid dose was 7.5 mg dexamethasone or equivalent (IQR:6-14 mg); 80.8% and 19.2% received low-dose and high-dose steroids, respectively. The median C-reactive protein level was >75 mg/L in majority of our cohort. The use of IL-6R antagonists alone or in combination was not associated with a significant difference in ventilator-free days (VFD) compared to steroids alone with different steroids regimens (adjusted incidence rate ratio [95% CI]): IL-6R antagonists (1.12 [0.88,1.4]), combination (0.83 [0.6,1.14]). Patients treated with low or high-dose steroids had non-significant differences in VFD compared to IL-6RA (ß=0.62, 95% CI −1.54,2.78 for low-dose steroid; ß=-1.19, 95% CI −3.85,1.47 for high-dose steroid). There was no difference in 28-day mortality and hospital mortality with IL-6RA alone or in combination compared to steroids alone (28-day mortality adjusted odds ratio [95% CI]): IL-6RA (0.68[0.44,1.07]), combination (1.07[0.67,1.70]). Sensitivity analysis findings were consistent with primary analysis. Liver dysfunction was higher in IL-6RA (p=0.04) while rate of bacteremia did not differ among groups.Conclusions In adult ICU COVID-19 patients on iMV, we found no difference in outcomes between those who received IL-6RA, steroids, or combination therapy and those who received IL-6RA or low-or high-dose steroids. Further randomized trials are needed to enhance our understanding for IL-6RA safety with different steroids regimen and the magnitude of benefit in those subgroups of patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04486521Funding StatementNo external funding was provided for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is approved by the Ethics Committee (office of research affair at King Faisal Specialist Hospital Project ID 2201053), The Society of Critical Care Medicine (SCCM) Scientific Review Committee, and SCCM Discovery Steering Committee. In some participating hospitals, verbal consent was obtained whereas in other countries the requirement for patient consent was waived by local research ethics committees. Local investigators were responsible for obtaining local approval in line with applicable regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current report are available from the corresponding author on reasonable request.